ReviewEuropean thyroid journal2013
Graves' orbitopathy: imperfect treatments for a rare disease.
Review in European thyroid journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search.Advances in therapy · 2015Pooled it
- Rehabilitative orbital decompression for Graves' orbitopathy: results of a randomized clinical trial.Journal of endocrinological investigation · 2018Trial
- Cardiovascular complications secondary to Graves' disease: a prospective study from Ukraine.PloS one · 2015Trial
- Article
- Dipeptidyl peptidase-4 inhibitors suppress myofibroblastic differentiation and hyaluronan synthesis in Graves' orbitopathy fibroblasts.Frontiers in endocrinology · 2026Article
- Unilateral Graves' Orbitopathy in a Patient with Marine-Lenhart Syndrome: A case report.Sultan Qaboos University medical journal · 2024Article
- Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves' orbitopathy.International ophthalmology · 2024Article
- Thyroid-Associated Optic Neuropathy: A Case Report of Optic Neuritis Due to Autoimmune Hypothyroidism.International medical case reports journal · 2024Article
- Changes in therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy.International ophthalmology · 2023Article
- Circulating miR-146a predicts glucocorticoid response in thyroid eye disease.European thyroid journal · 2023Article
- Differentially expressed genes in orbital adipose/connective tissue of thyroid-associated orbitopathy.PeerJ · 2023Article
- Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy.International journal of molecular sciences · 2022Article
- Current concepts regarding Graves' orbitopathy.Journal of internal medicine · 2022Review
- Acute Pericarditis as an Uncommon Presentation of Graves' Disease.Oman medical journal · 2022Article
- Multidisciplinary approach to orbital decompression. A review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2021Review
- Effects of glucocorticoid pulse therapy on thyroid function and thyroid antibodies in children with graves' disease.Italian journal of pediatrics · 2021Article
- Is concomitant treatment with steroids and radiotherapy more favorable than sequential treatment in moderate-to-severe graves orbitopathy?La Radiologia medica · 2021Article
- Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?Frontiers in endocrinology · 2021Article
- Thyroid eye disease: current and potential medical management.International ophthalmology · 2020Review
- Preclinical studies on the toxicology, pharmacokinetics and safety of K1-70Auto- immunity highlights · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' orbitopathy (GO) is the most frequent and invalidating extrathyroidal expression of Graves' disease. Its incidence and prevalence are, however, low. About three quarters of Graves' patients have no GO at diagnosis, and moderate-to-severe and severe forms represent no more that 5-6% of cases. Progression to severe forms occurs rarely, but it may be caused by risk factors, the most important being smoking and poor control of thyroid dysfunction. Lot of progress has been recently achieved in the understanding of GO pathogenesis, while the disease remains a therapeutic challenge and dilemma. Common treatments for moderate-to-severe and active forms of GO (glucocorticoids and orbital radiotherapy) frequently provide incomplete responses and may be followed by relapse or progression of GO. After the disease has been inactivated by medical treatment, many patients need rehabilitative surgery for residual manifestations (orbital decompression for exophthalmos, squint surgery for extraocular muscle dysfunction, eyelid surgery for eyelid malposition). Novel pharmacological treatments are on the horizon and might target pathogenetic mechanisms of the disease better than glucocorticoids. Clinical evidence concerning their efficacy and safety is presently lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.